Viridian Therapeutics Inc (VRDN) - Total Assets
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) holds total assets worth $789.02 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Viridian Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Viridian Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Viridian Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Viridian Therapeutics Inc's total assets of $789.02 Million consist of 99.4% current assets and 0.6% non-current assets. Review total liabilities of Viridian Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Viridian Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viridian Therapeutics Inc's current assets represent 99.4% of total assets in 2025, an increase from 59.8% in 2012.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2025, up from 4.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Viridian Therapeutics Inc Competitors by Total Assets
Key competitors of Viridian Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Viridian Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.15 | 19.49 | 6.86 |
| Quick Ratio | 15.15 | 19.49 | 6.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $732.94 Million | $623.51 Million | $98.63 Million |
Viridian Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Viridian Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.46 |
| Latest Market Cap to Assets Ratio | 1.90 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | $899.42 Million |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Viridian Therapeutics Inc's assets above their book value (1.90x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Viridian Therapeutics Inc's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $899.42 Million | +21.15% |
| 2024-12-31 | $742.40 Million | +51.38% |
| 2023-12-31 | $490.42 Million | +12.72% |
| 2022-12-31 | $435.09 Million | +113.58% |
| 2021-12-31 | $203.71 Million | +55.20% |
| 2020-12-31 | $131.25 Million | +333.73% |
| 2019-12-31 | $30.26 Million | -54.25% |
| 2018-12-31 | $66.15 Million | +26.04% |
| 2017-12-31 | $52.48 Million | +1132.24% |
| 2016-12-31 | $4.26 Million | -66.99% |
| 2015-12-31 | $12.90 Million | +59.50% |
| 2014-12-31 | $8.09 Million | +120.25% |
| 2013-12-31 | $3.67 Million | +32.08% |
| 2012-12-31 | $2.78 Million | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more